Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.35 |
| ▸ | KLK7 | P49862 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 4/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6853156 | 1.00 | ELANE (0.37) | ELANEGPR119KLK7PDE4APDE4B | |
| SCHEMBL6853151 | 1.00 | ELANE (0.37) | ELANEGPR119KLK7PDE4APDE4B | |
| SCHEMBL5887148 | 0.89 | ELANE (0.46) | ELANEGPR119KLK7RIPK1KDM4E | |
| SCHEMBL5887150 | 0.89 | ELANE (0.46) | ELANEGPR119KLK7RIPK1KDM4E | |
| SCHEMBL6333635 | 0.89 | ELANE (0.46) | ELANEGPR119KLK7RIPK1KDM4E | |
| SCHEMBL5745497 | 0.89 | ELANE (0.46) | ELANEGPR119KLK7RIPK1KDM4E | |
| SCHEMBL6859829 | 0.87 | TSHR (0.42) | GPR119RIPK1KDM4EGAATSHR | |
| SCHEMBL6859826 | 0.87 | TSHR (0.42) | GPR119RIPK1KDM4EGAATSHR | |
| SCHEMBL6859824 | 0.87 | TSHR (0.42) | GPR119RIPK1KDM4EGAATSHR | |
| SCHEMBL7090716 | 0.85 | ELANE (0.38) | ELANEGPR119KLK7PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794523-B2 | ANTICANCER AGENTS, ANTITUMOR AGENTS; LEUKEMIA | FLORIDA STATE UNIVERSITY | 2004-09-21 | — | — | US | disclosed |
| US-20030065200-A1 | Anticancer agents, antitumor agents; leukemia | FLORIDA STATE UNIVERSITY | 2003-04-03 | — | — | US | disclosed |
| EP-0690712-B1 | TAXANES HAVING A PYRIDYL SUBSTITUTED SIDE-CHAIN | UNIV FLORIDA STATE (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6018073-A | Tricyclic taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them | FLORIDA STATE UNIVERSITY (US) | 2000-01-25 | — | — | US | disclosed |
| US-5760219-A | CHEMICAL INTERMEDIATES FOR PREPARING TAXANES ANTITUMOR AGENTS | FLORIDA STATE UNIVERSITY (US) | 1998-06-02 | — | — | US | disclosed |
| US-5739362-A | ANTILEUKEMIA, ANTITUMOR AGENTS | FLORIDA STATE UNIVERSITY (US) | 1998-04-14 | — | — | US | disclosed |
| US-5489601-A | ANTILEUKEMIA, ANTITUMOR AGENTS | FLORIDA STATE UNIVERSITY (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0690712-A1 | TAXANES HAVING A PYRIDYL SUBSTITUTED SIDE-CHAIN | FLORIDA STATE UNIVERSITY (US) | 1996-01-10 | — | — | EP | disclosed |
| EP-0690712-A4 | TAXANES HAVING A PYRIDYL SUBSTITUTED SIDE-CHAIN | UNIV FLORIDA STATE (US) | 1995-11-20 | — | — | EP | disclosed |
| WO-1994021252-A1 | TAXANES HAVING A PYRIDYL SUBSTITUTED SIDE-CHAIN | FLORIDA STATE UNIVERSITY (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065200-A1 | Anticancer agents, antitumor agents; leukemia | MCL1, BCL3, TOP2A | ELANE 671/4885GPR119 3598/4885KLK7 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.